Trial Profile
A prospective, randomised, open, crossover patient preference study comparing oral immediate release and transdermal oxybutynin in overactive bladder patients.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Mar 2012
Price :
$35
*
At a glance
- Drugs Oxybutynin (Primary) ; Oxybutynin
- Indications Overactive bladder
- Focus Therapeutic Use
- Acronyms Oxy-OAB-Skin-Oxy
- 29 May 2007 New trial record.